PAVmed IncNASDAQ:PAVMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.0000
- TODAY'S CHANGE (%)-0.0100 (-0.9901%)
- Bid / Lots1.0000/ 1
- Ask / Lots1.0600/ 1
- Open / Previous Close1.0000 / 1.0100
- Day Range
- 52 Week Range
- Volume54,711
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PAVM |
|---|---|---|
| 09:32 ET | 773 | 1 |
| 09:33 ET | 1300 | 1.01 |
| 09:37 ET | 2605 | 1.01 |
| 09:42 ET | 2338 | 1.01 |
| 09:46 ET | 100 | 1.02 |
| 09:50 ET | 1100 | 1.02 |
| 09:53 ET | 200 | 1.02 |
| 10:00 ET | 2000 | 1.0215 |
| 10:29 ET | 766 | 1.02 |
| 10:31 ET | 500 | 1.015 |
| 10:38 ET | 3833 | 1.018 |
| 10:44 ET | 133 | 1.03 |
| 10:49 ET | 200 | 1.0065 |
| 10:56 ET | 1000 | 1.015 |
| 11:00 ET | 100 | 1.015 |
| 11:07 ET | 249 | 1.015 |
| 11:20 ET | 4963 | 1.005 |
| 11:45 ET | 500 | 1.01 |
| 11:50 ET | 300 | 1.01 |
| 12:06 ET | 100 | 1 |
| 12:14 ET | 205 | 1.0027 |
| 12:19 ET | 100 | 0.9951 |
| 12:26 ET | 715 | 1 |
| 12:32 ET | 500 | 1 |
| 12:35 ET | 134 | 0.9901 |
| 12:50 ET | 500 | 1 |
| 12:53 ET | 400 | 1 |
| 01:02 ET | 100 | 1.01 |
| 01:47 ET | 206 | 0.99 |
| 01:56 ET | 300 | 0.9998 |
| 01:58 ET | 200 | 0.9998 |
| 02:00 ET | 268 | 0.99 |
| 02:03 ET | 100 | 0.9989 |
| 02:07 ET | 1000 | 0.997079 |
| 02:09 ET | 800 | 0.9958 |
| 02:16 ET | 1836 | 1 |
| 02:27 ET | 604 | 1.004 |
| 02:43 ET | 200 | 1 |
| 02:45 ET | 400 | 1 |
| 02:48 ET | 600 | 1 |
| 02:50 ET | 3902 | 1.005 |
| 03:01 ET | 100 | 1.005 |
| 03:19 ET | 250 | 1.0007 |
| 03:24 ET | 800 | 1.005 |
| 03:37 ET | 1332 | 1 |
| 03:44 ET | 220 | 1.0001 |
| 03:48 ET | 10199 | 1.005 |
| 03:50 ET | 300 | 1.01 |
| 04:00 ET | 1179 | 1 |
Nov 20, 2024
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard(R) Esophageal DNA Test, from 7:56AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:56AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, from 8:15AM ET on Monday Nov 18, 2024 by Dow Jones
8:15AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 14, 2024
Press Release: PAVmed Provides Business Update and Third Quarter 2024 Financial Results, from 8:01AM ET on Thursday Nov 14, 2024 by Dow Jones
8:01AM ET on Thursday Nov 14, 2024 by Dow JonesPAVmed Provides Business Update and Third Quarter 2024 Financial Results, from 8:01AM ET on Thursday Nov 14, 2024 by Dow Jones
8:01AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PAVmed Inc | 10.4M | -0.2x | --- |
BioElectronics Corp | 7.4M | -15.0x | --- |
ADM Tronics Unlimited Inc | 5.4M | -18.2x | --- |
Longport Inc | 2.3K | 0.0x | --- |
Aksys Ltd | 30.0 | 0.0x | --- |
Optimus Healthcare Services Inc | 1.6M | -0.2x | --- |
Company Information
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Contact Information
- Headquarters
- 360 Madison Avenue, 25Th FloorNEW YORK, NY, United States 10017
- Phone
- 212-949-4319
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Lishan Aklog
- President, Chief Financial Officer
- Dennis Mcgrath
- Independent Vice Chairman of the Board
- Michael Glennon
- Chief Operating Officer, Executive Vice President
- Shaun O'Neil
- Chief Technology Officer, Chief Compliance Officer
- Brian Deguzman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.4M |
|---|---|
Revenue (TTM) | $4.0M |
Shares Outstanding | 10.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-4.35 |
Book Value | $-6.28 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 2.6 |
Price/Cash Flow (TTM) | 4.9x |
Operating Margin | 280.64% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
